Evidence map›Paper›PMID 35912006›Full record

ReviewJournal of Cancer2022

Role and mechanism of miR-211 in human cancer.

Lingling Ye, Fen Wang, Jinyan Wang, Hao Wu, Hui Yang, Zhaohui Yang, Haiwei Huang

Open access · goldAbstract readReview
In one paragraph

Review in Journal of Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Epigenetic regulation of EZH2 by ncRNAs: mechanisms and oncogenic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lingling YeDepartment of Gynecology, Zhangjiagang First People's Hospital, Zhangjiagang Affiliated Hospital of Soochow University, Zhangjiagang, Jiangsu, China; Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Fen WangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Jinyan WangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Hao WuDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Hui YangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Zhaohui YangDepartment of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Haiwei HuangDepartment of Gynecology, Zhangjiagang First People's Hospital, Zhangjiagang Affiliated Hospital of Soochow University, Zhangjiagang, Jiangsu, China; Department of Oncology, The Affiliated Jiangning Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
Nanjing Medical University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MircoRNA (miRNA), which are a group of small, and highly conserved non-coding RNA consisting of 18-25 nucleotides, can modulate gene expression at post-transcriptional level, through complementary binding to the 3'-untranslated region (3'-UTR) of numerous target genes. Emerging evidence indicates that miRNAs play critical roles in tumorigenesis and progression of cancer. Among them, miR-211 has been extensively studied in multiple cancers. The expression of miR-211 significantly varies with cancer types and may be used as a potential prognostic marker for cancer. MiR-211 can regulate multiple biological processes in cancer, including proliferation, apoptosis, metastasis and drug resistance. Additionally, several factors may contribute to the dysregulation of miR-211 in cancer. Consequently, this review aims to discuss the novel findings that highlight latent value of miR-211 in the prognosis assessment and treatment of cancer.

Identifiers

PMID35912006
PMCPMC9330454
OpenAlexW4288085592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.